Operator of an immunotherapy company intended to discover and develop multiple candidate molecules. The company's patent portfolio exemplifies the use of antibodies, antibody fragments, RNA/DNA, Aptamers and small molecules as targeting domains, enabling healhcare institutes to access the technology for the treatment of both solid tumours and leukemia.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Seed Round | 01-Aug-2020 | $4M | 00.000 | Completed | Generating Revenue | |
3. Corporate | 06-Aug-2019 | 00000 | 00.000 | 0000 | Completed | Generating Revenue |
2. Corporate | 03-Aug-2018 | $1.84M | $1.84M | 000.00 | Completed | Generating Revenue |
1. Joint Venture | 02-Mar-2016 | $110M | 00000 | Completed | Startup |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Nick Staples Ph.D | Interim Chief Executive Officer |
Name | Representing | Role | Since |
---|---|---|---|
Jonathan Synett | Centauri Therapeutics | Board Member | 000 0000 |
Michael Westby Ph.D | Centauri Therapeutics | Board Member | 000 0000 |
Pauline Stasiak Ph.D | LifeArc | Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Government of UK | Government | Minority | 000 0000 | 000000 0 | |
LifeArc | Venture Capital | Minority | 000 0000 | 000000 0 | |
NCL Technology Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Centauri Therapeutics | PE-Backed Company | Majority | 000 0000 | 000000 0 | |
Horizon Discovery | Corporation | Minority | 000 0000 | 000000 0 |